BIOCON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 267.2 INR | +1.31% |
|
-3.99% | +7.03% |
| Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
| Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
| Sales 2024 * | 145B 1.74B | Sales 2025 * | 167B 1.99B | Capitalization | 319B 3.82B |
|---|---|---|---|---|---|
| Net income 2024 * | 9.49B 114M | Net income 2025 * | 9.3B 111M | EV / Sales 2024 * | 3.16 x |
| Net Debt 2024 * | 139B 1.66B | Net Debt 2025 * | 142B 1.7B | EV / Sales 2025 * | 2.77 x |
| P/E ratio 2024 * |
33.6
x | P/E ratio 2025 * |
37.4
x | Employees | 16,545 |
| Yield 2024 * |
0.5% | Yield 2025 * |
0.55% | Free-Float | 37.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biocon Limited
More recommendations
More press releases
More news
| 1 day | +1.31% | ||
| 1 week | -3.99% | ||
| Current month | +1.15% | ||
| 1 month | +6.60% | ||
| 3 months | -4.67% | ||
| 6 months | +11.96% | ||
| Current year | +7.03% |
1 week
262.10
275.50
1 month
244.55283.20
Current year
244.55307.10
1 year
217.50307.10
3 years
191.55420.25
5 years
191.55487.75
10 years
65.88487.75
| Managers | Title | Age | Since |
|---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 13-04-30 |
Peter Bains
CEO | Chief Executive Officer | 65 | 22-12-11 |
| Chairman | 71 | 78-11-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 78-11-28 | |
| Director/Board Member | 69 | 99-12-31 | |
| Director/Board Member | 60 | 18-07-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 267.2 | +1.31% | 9,499,931 |
| 24-04-16 | 263.8 | -0.57% | 3,484,465 |
| 24-04-15 | 265.2 | -3.19% | 4,071,926 |
| 24-04-12 | 274 | -1.55% | 6,929,503 |
| 24-04-10 | 278.3 | +2.58% | 14,611,970 |
Delayed Quote NSE India S.E., April 18, 2024 at 07:43 am EDT
More quotes
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Calendar
2024-05-15
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
267.2
INR
Average target price
279.1
INR
Spread / Average Target
+4.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.03% | 3.76B | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- BIOCON Stock
